KRAS G12C inhibitors and methods of using the same

US11285135B2 · kind B2 · utility

Assignee

• AMGEN INC. · US

Inventors

• Brian Alan LANMAN · Calabasas, US
• Victor J. Cee · Thousand Oaks, US
• Alexander J. Pickrell · Westlake Village, US
• Anthony B. Reed · Newbury Park, US
• Kevin Yang · San Gabriel, US
• David John Kopecky · West Hollywood, US
• Hui-Ling Wang · Thousand Oaks, US
• Patricia Lopez · Calabasas, US
• Kate Ashton · Thousand Oaks, US
• Shon Booker · Thousand Oaks, US
• Christopher M. Tegley · Thousand Oaks, US

Key dates

• Filing date: Nov 5, 2019
• Grant date: Mar 29, 2022
• Expiry date: Nov 5, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are methods of treating cancer with KRAS G12C inhibitors of Formula I and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.